Revolo Biotherapeutics   Report issue

For profit Phase 1 Phase 2
Founded: Stevenage United Kingdom (2011)

Organization Overview

First Clinical Trial
2017
NCT03058458
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer, Revolo Biotherapeutics | Immune Regulation | Revolo Biotherapeutics